Athenex Stock

Athenex EBIT per Employee

Delisted

The EBIT per Employee of Athenex (ATNX) as of Aug 24, 2026 is -117,934.23 USD. In the previous year, EBIT per Employee was -193,887.02 USD — a change of -39.17% (higher).

EBIT per Employee

-117,934.23USD

YoY

-39.17%

Last updated:

EBIT per Employee of Athenex is 2026 -117,934.23 USD. EBIT per Employee of Athenex was 2025 -193,887.02 USD. It decreases by -39.17% higher compared to the previous year.

The Athenex EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2015
-85,510.96 USD
Jan 1, 2016
-145,497.47 USD
Jan 1, 2017
-211,084.32 USD
Jan 1, 2018
-213,858.35 USD
Jan 1, 2019
-201,571.67 USD
Jan 1, 2020
-208,639.12 USD
Jan 1, 2021
-193,887.02 USD
Jan 1, 2022
-117,934.23 USD
The Athenex EBIT per Employee history
YEAREBIT per EmployeeYoY
-117,934.23USD-39.17%
-193,887.02USD-7.07%
-208,639.12USD+3.51%
-201,571.67USD-5.75%
-213,858.35USD+1.31%
-211,084.32USD+45.08%
-145,497.47USD+70.15%
-85,510.96USD+186.99%
-29,795.95USD
Access this data via the Eulerpool API

Athenex Stock analysis

What does Athenex do? Athenex Inc was founded in 2003 and is headquartered in Buffalo, New York. The company specializes in the development and marketing of innovative drugs and therapies for the treatment of cancer and other serious diseases. Athenex's business model is based on collaboration with other companies and research institutions. The company works closely with academic partners to identify and develop new technologies and active ingredients. Athenex has also entered into several collaboration agreements with major pharmaceutical companies to facilitate the marketing of its products. The company has multiple divisions: Athenex Pharmaceutical Division, Athenex Oncology Division, and Athenex Pharmaceutical Technology Division. The Athenex Pharmaceutical Division focuses on the development and marketing of drugs for the treatment of cancer and other serious illnesses. The company has several promising drug candidates in its pipeline, including Oratopo, a drug for the treatment of breast cancer, and KX-2-391, a drug for the treatment of prostate cancer. The Athenex Oncology Division focuses on the development and marketing of innovative cancer treatment methods. The company has several promising therapy approaches in its pipeline, including an immunological cancer treatment based on activating the immune system to fight cancer cells. The Athenex Pharmaceutical Technology Division utilizes advanced technologies to improve the effectiveness and tolerability of drugs, including novel drug delivery systems and innovative packaging forms. Athenex also offers a wide range of products and services for the pharmaceutical industry, including drug development and manufacturing, as well as the supply of active ingredients and excipients. Overall, Athenex has a broad and interesting business model and a promising portfolio of drug candidates and therapy approaches in its pipeline. The company has also established strong partnerships with other companies and research institutions to advance its development and marketing of drugs and therapies. Athenex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athenex stock

EBIT per Employee of Athenex is -117,934.23 USD in 2026.

EBIT per Employee of Athenex changed from -193,887.02 USD to -117,934.23 USD, representing a -39.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Athenex since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Athenex historically and in real time.

Access this data via the Eulerpool API

Workforce — Athenex

All Key Metrics — Athenex